Abbie Celniker

Biography

Abbie Celniker is a partner at Third Rock Ventures, and has 30 years of experience in R&D and senior leadership roles. Abbie focuses on the formation, development and strategy of Third Rock's portfolio companies. Prior to joining Third Rock Ventures, she served as president and CEO of Eleven Biotherapeutics since 2011. Previously, Abbie was the president and CEO of Taligen Therapeutics from 2008 to 2011. Abbie is the chair of MassBio's board of directors, a member of the board of ImaginAb, where she was previously the chair, and a member of the scientific advisory board for Adimab. She is also a member of the board of directors of the nonprofit Unitio and T1D. She has a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Molecular Biology from the University of Arizona. 

Research Interest

 Discovering and developing precision therapies for patients with kidney disease